Recherche :  
 









Accueil

***APOGÉE-Net/CanGèneTest ­ EuroGentest Ancillary Meeting at the International Congress of Human Genetics in Montreal October 13 2011***
At the 12th International Congress of Human Genetics held in Montreal in October 2011, EuroGentest and APOGEE-Net/CanGeneTest jointly organized a session entitled "Challenges in the Translation of Genomic Innovations into Clinical Care". The session was opened by François Rousseau (Université Laval) who presented the APOGEE-Net/CanGeneTest Network and its role in addressing the challenges of translating genomic and genetic innovations into the health care system. Gert Matthijs (University of Leuven) presented the EuroGentest Network and its role in the improvement and standardization of quality in genetic testing. Joris Vermeesch (University of Leuven) described two pilot studies of external quality assessment of constitutional molecular karyotyping, and  Helena Kääriäinen (University of Helsinki) described the impact of the increasing importance of genetic testing in health care. Daniel Reinharz (Université Laval) presented cost/effectiveness and cost/utility simulations for selected genetic and genomic health innovations, and Renaldo Battista (Université de Montréal) discussed the role of health technology assessment in the translational process.
 
The session was a success as it attracted over 60 participants despite the concurrent presentation of several other events, underlining the importance of these questions to the medical and scientific community. One of the conclusions of this event was that there is strong complementarity between the activities of each Network and that there is room for even more synergy between the different teams working in this area. More information on the session can be obtained by following this link :
http://www.eurogentest.org/web/info/public/ICHG_AncillaryEvent2011.xhtml=


APOGEE-Net/CanGèneTest est un réseau international de recherche et de connaissances étudiant les défis posés par les soins et les politiques de santé incluant ceux reliés aux services de génétique de laboratoire. Son objectif général est d'améliorer le transfert technologique d'innovations génétiques qui sont utiles au plan clinique et d'un rapport coût/efficacité intéressant vers le système de santé, ainsi que de stimuler le développement de politiques de santé éclairées par les données probantes. Utilisant une approche multidisciplinaire, nous visons à étudier le cheminement du test génétique, de sa découverte dans le laboratoire de recherche fondamentale jusqu'à son utilisation dans un contexte clinique. De plus, grâce à notre bulletin électronique et ce site WEB, nous espérons contribuer à la dissémination d'une information juste et pertinente à tous nos collègues intéressés par ce domaine de la recherche, en aval de la découverte des gènes, mais nécessaire pour traduire les découvertes cliniquement valides et utiles en soins de santé innovateurs.

Paru récemment dans le bulletin :


21 janv 2012
How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care (restricted access)
This article discusses how some of these emerging novel molecular diagnostic technologies and analytes, such as next-generation sequencing, chromosomal microarray, microRNAs and circulating fetal nucleic acids are revolutionizing patient care and personalized medicine.
 
21 janv 2012
Consultation on newborn screening for Thalassaemia
The NHS Sickle Cell and Thalassaemia Screening Programme is seeking the views of stakeholders and interested parties on the recent report - Newborn Screening for Thalassaemia. All comments must be received by 21st March 2012. Original report: Newborn Screening for Thalassaemia
 
21 janv 2012
Screening in the UK 2010-11: Effective Policies and Programmes
Annual report from the UK National Screening Committee, focusing on policy development and screening programmes across the UK. Related document: Screening in England 2010-11
 
21 janv 2012
Most parents who get tested for breast cancer genes share results with their children
A new study has found that when parents get tested for breast cancer genes, many of them share their results with their children, even with those who are very young. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that most parents think that their children are not distressed when they learn about the test results. Original study: When parents disclose BRCA1/2 test results: Their communication and perceptions of offspring response
 
21 janv 2012
Health care providers and direct-to-consumer access and advertising of genetic testing in the United States (restricted access)
This review provides a brief overview of direct-to-consumer (DTC) advertising and the regulation of pharmaceuticals and genetic tests in the United States. It highlights recent changes in the regulatory culture regarding genetic tests that are sold to consumers, and discusses the impact on health care providers of selling and advertising genetic tests directly to consumers.